Investigates IL-10’s role in curcumin's alleviation of intervertebral disc degeneration, suggesting therapeutic potential.
BACKGROUND: The pathogenesis of intervertebral disc degenerative disease (IDDD) remains unclear. While the anti-inflammatory role of IL-10 and the therapeutic potential of curcumin are well recognized, their specific interplay in IDDD remains poorly understood. OBJECTIVES: This study aimed to investigate whether curcumin alleviates IDDD by upregulating IL-10 to suppress MAPK pathway overactivation, thereby exerting anti-inflammatory, anti-apoptotic and pro-anabolic effects on nucleus pulposus cells. METHODS: Nucleus pulposus cells were isolated from patients with IDDD and divided into the following groups: control, varying concentrations of curcumin (10-80) μmol/L, varying concentrations of IL-10 (30-60) mM and a combination group of curcumin and IL-10. Cell proliferation and gene/protein expression were assessed using MTT assay, qPCR, Western blot and ELISA. RESULTS: IL-10 promoted myeloid cell proliferation, upregulated Bax and GAG expression, enhanced collagen II synthesis and ERK1/2 phosphorylation, while downregulating Bcl-2 expression and reducing TNF-α and IL-6 secretion (P<0.05). These effects exhibited a dose-dependent enhancement, with high-dose IL-10 showing significantly greater efficacy compared to the low-dose group (P<0.05). CONCLUSION: IL-10 mitigates disc degeneration by modulating MAPK signaling, reducing inflammation and apoptosis and promoting matrix synthesis in nucleus pulposus cells.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: